Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial
Objective. Vitiligo is a common, autoimmune disease that results in the destruction of the melanocytes and manifests as depigmented macules on various areas of the skin. Numerous treatment options have been proposed for vitiligo. The purpose of this study was to compare the efficacy of microneedling...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Dermatology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2021/5652140 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832546005332000768 |
|---|---|
| author | Fariba Iraji Ali Asilian Zahra Talebzadeh Mina Saber Fatemeh Mokhtari Amirhossein Siadat Seyed Mohsen Hosseini |
| author_facet | Fariba Iraji Ali Asilian Zahra Talebzadeh Mina Saber Fatemeh Mokhtari Amirhossein Siadat Seyed Mohsen Hosseini |
| author_sort | Fariba Iraji |
| collection | DOAJ |
| description | Objective. Vitiligo is a common, autoimmune disease that results in the destruction of the melanocytes and manifests as depigmented macules on various areas of the skin. Numerous treatment options have been proposed for vitiligo. The purpose of this study was to compare the efficacy of microneedling plus topical pimecrolimus 1% versus the sole use of topical pimecrolimus 1% for the treatment of vitiligo. Methods. This clinical trial was conducted on 30 skin lesions on 15 Al-Zahra hospital patients. Each patient had two similar lesions in the limb area, and each lesion was considered a separate treatment group. The left or right side of the patient’s lesion was randomly assigned to receive microneedling plus topical pimecrolimus for three months, while the other side received only topical pimecrolimus 1%. As part of the follow-up, digital photography was taken at the baseline and biweekly for three months after treatment and six months’ follow-up. The following methods were used to evaluate the results: DLQI questionnaires, patient satisfaction questionnaires, and two independent dermatologists comparing the improvement rate for each group. Results. Topical pimecrolimus 1% treatment led to unsatisfactory results, whereas the combination of microneedling and topical pimecrolimus1% treatment produced a more favorable overall outcome (P<0.001). Conclusion. This study established that combination therapy results in more significant patient improvement. Additionally, one patient experienced mild skin irritation as a side effect of topical pimecrolimus. |
| format | Article |
| id | doaj-art-a52b9172b46841e7922e19ff21222f0a |
| institution | Kabale University |
| issn | 1687-6113 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Dermatology Research and Practice |
| spelling | doaj-art-a52b9172b46841e7922e19ff21222f0a2025-02-03T07:24:11ZengWileyDermatology Research and Practice1687-61132021-01-01202110.1155/2021/5652140Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical TrialFariba Iraji0Ali Asilian1Zahra Talebzadeh2Mina Saber3Fatemeh Mokhtari4Amirhossein Siadat5Seyed Mohsen Hosseini6Department of DermatologyDepartment of DermatologyDepartment of DermatologyDepartment of DermatologyDepartment of DermatologyDepartment of DermatologyDepartment of DermatologyObjective. Vitiligo is a common, autoimmune disease that results in the destruction of the melanocytes and manifests as depigmented macules on various areas of the skin. Numerous treatment options have been proposed for vitiligo. The purpose of this study was to compare the efficacy of microneedling plus topical pimecrolimus 1% versus the sole use of topical pimecrolimus 1% for the treatment of vitiligo. Methods. This clinical trial was conducted on 30 skin lesions on 15 Al-Zahra hospital patients. Each patient had two similar lesions in the limb area, and each lesion was considered a separate treatment group. The left or right side of the patient’s lesion was randomly assigned to receive microneedling plus topical pimecrolimus for three months, while the other side received only topical pimecrolimus 1%. As part of the follow-up, digital photography was taken at the baseline and biweekly for three months after treatment and six months’ follow-up. The following methods were used to evaluate the results: DLQI questionnaires, patient satisfaction questionnaires, and two independent dermatologists comparing the improvement rate for each group. Results. Topical pimecrolimus 1% treatment led to unsatisfactory results, whereas the combination of microneedling and topical pimecrolimus1% treatment produced a more favorable overall outcome (P<0.001). Conclusion. This study established that combination therapy results in more significant patient improvement. Additionally, one patient experienced mild skin irritation as a side effect of topical pimecrolimus.http://dx.doi.org/10.1155/2021/5652140 |
| spellingShingle | Fariba Iraji Ali Asilian Zahra Talebzadeh Mina Saber Fatemeh Mokhtari Amirhossein Siadat Seyed Mohsen Hosseini Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial Dermatology Research and Practice |
| title | Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial |
| title_full | Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial |
| title_fullStr | Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial |
| title_full_unstemmed | Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial |
| title_short | Microneedling in Combination with Topical Pimecrolimus 1% versus Topical Pimecrolimus 1% for the Treatment of Refractory Stable Vitiligo: A Randomized Clinical Trial |
| title_sort | microneedling in combination with topical pimecrolimus 1 versus topical pimecrolimus 1 for the treatment of refractory stable vitiligo a randomized clinical trial |
| url | http://dx.doi.org/10.1155/2021/5652140 |
| work_keys_str_mv | AT faribairaji microneedlingincombinationwithtopicalpimecrolimus1versustopicalpimecrolimus1forthetreatmentofrefractorystablevitiligoarandomizedclinicaltrial AT aliasilian microneedlingincombinationwithtopicalpimecrolimus1versustopicalpimecrolimus1forthetreatmentofrefractorystablevitiligoarandomizedclinicaltrial AT zahratalebzadeh microneedlingincombinationwithtopicalpimecrolimus1versustopicalpimecrolimus1forthetreatmentofrefractorystablevitiligoarandomizedclinicaltrial AT minasaber microneedlingincombinationwithtopicalpimecrolimus1versustopicalpimecrolimus1forthetreatmentofrefractorystablevitiligoarandomizedclinicaltrial AT fatemehmokhtari microneedlingincombinationwithtopicalpimecrolimus1versustopicalpimecrolimus1forthetreatmentofrefractorystablevitiligoarandomizedclinicaltrial AT amirhosseinsiadat microneedlingincombinationwithtopicalpimecrolimus1versustopicalpimecrolimus1forthetreatmentofrefractorystablevitiligoarandomizedclinicaltrial AT seyedmohsenhosseini microneedlingincombinationwithtopicalpimecrolimus1versustopicalpimecrolimus1forthetreatmentofrefractorystablevitiligoarandomizedclinicaltrial |